To mimic the effect of LOC339803 in the activation of a proinflammatory response in IBD, we used an interferon gamma (IFNG) stimulation model, described to alter m6A methylation levels in intestinal cells.[45] With the aim of reducing IFNG‐induced inflammation in these cells, we knocked down LOC339803 by CRISPR‐Cas9 in HCT‐15 cells (Figure 4D). Here, IFNG is linked to inflammatory bowel disease.